Genesis Biotechnology Group
Menu

Leadership

  • Olesia Buiakova
  • Brian McGuinness
  • James Beasely
  • Prabal Banerjee

Olesia Buiakova, M.D., Ph.D.

Chief Scientific Officer, GD3

Dr. Buiakova joined the GBG team in 2013. As the Chief Scientific Officer of Invivotek oversees a multidisciplinary pre-clinical contract research team of Ph.D., MS, and BS scientists dedicated to evaluating therapeutic approaches in the areas of oncology, immunology, metabolic and infectious diseases. She is responsible for establishing and managing pre-clinical animal research programs for several big Pharma and biotech companies, including in vivo pharmacology programs for sister companies at GBG. Dr. Buiakova identifies opportunities for new collaborations and serves as a member of GBG Executive Council.

Extra Info

Dr. Buiakova began her career with GBG as the Vice President of Biology for Invivotek in 2013. Later that year, she transitioned into her current role as Chief Scientific Officer.

Prior to joining GBG, Dr. Buiakova held multiple positions of increasing responsibility including Director at Taconic CRO Division (formerly Xenogen Biosciences) with a concentration in in vivo pharmacology. She also spent three years at Columbia Genome Center at Columbia University, New York, NY concentrating on animal models of human disease.

Dr. Buiakova earned an MD in Medical Biochemistry at the Russian State Medical University in Moscow, Russia. She earned a Ph.D. in Molecular Biology at the Institute for Molecular Genetics of Russian Academy of Sciences in Moscow, Russia. Dr. Buiakova completed her post-doctoral fellowship in Molecular Neurobiology at Hoffmann-La Roche Institute for Molecular Biology in Nutley NJ.

Brian McGuinness, Ph.D.

Director of Chemistry, Venenum Biodesign

Dr. McGuinness joined the GBG team in 2010. As the Director of Chemistry, he oversees a team of medicinal chemists in the optimization of small molecule therapeutic compounds aimed at immuno-oncology targets, metabolic disorders, and infectious disease. He also guides the bioanalytical characterization of lead molecules through pharmacokinetic and Absorption, Distribution, Metabolism and Excretion (ADME) studies. In addition, Dr. McGuinness is responsible for the maintenance and growth of Venenum’s 5.7 million member compound collection for high-throughput screening.

Extra Info

Dr. McGuinness began his career with VENENUM Biodesign as the Medicinal Chemistry Team Leader. In 2014 he was promoted to his current position as Director of Chemistry.

Dr. McGuinness brought 17 years of experience in the Pharmeceutical, Peptide and Medicinal Chemistry industries. He previously held positions with PerSeptive Biosystems as a Senior Scientist, Pharmacopeia as a Senior Principal Scientist, and Ligand Pharmaceuticals as a Senior Research Investigator.

Dr. McGuinness received his BS in Chemistry from St. Joseph’s University in Philadelphia, PA. He earned his M. Phil.; PhD. in Organic Chemistry at Columbia University in New York, NY. Dr. McGuinness completed his National Institutes of Health (NIH) post-doctoral fellowship in Organic Chemistry from the Massachusetts Institute of Technology.

James Beasely, Ph.D.

Director of Biology, Venenum Biodesign

Dr. Beasley joined the GBG team in 2011. As Venenum’s Director of Biology, he oversees a team of scientists that support the research efforts in GBG’s pre-clinical drug discovery programs in therapeutic areas such as metabolic disorders, oncology, and infectious disease. Dr. Beasley’s Discovery Biology team specializes in the development, optimization, and execution of assays in the ultra-high-throughput screening (uHTS) of Venenum’s 5.7 million member compound library. The team also develops and performs assays, including several ADME-Tox assays, necessary to profile the small molecule therapeutic compounds produced by medicinal chemistry. Dr. Beasley serves as a member of the GBG Executive Council.

Extra Info

Dr. Beasley began his career with VENENUM Biodesign as the Discovery Biology Team Leader. In 2014 he was promoted to his current position as Director of Discovery Biology.

Dr. Beasley brought 12 years of experience in the Drug Discovery industry. He previously held positions with Ligand Pharmaceuticals as a Senior Research Investigator, Pharmacopeia as a Senior Principal Scientist, and DGI Biotechnology as a Senior Scientist.

Dr. Beasley received his BS in Chemistry from University of Texas at Austin in Austin, TX. He earned his PhD. in Chemistry at University of North Carolina at Chapel Hill in Chapel Hill, NC. Dr. Beasley completed his post-doctoral fellowship at Princeton University in Princeton, NJ.

Prabal Banerjee, Ph.D.

Business Development Executive, GD3

Prabal joined the GD3 team in 2017. As a Business Development Executive, he is responsible for developing the overall marketing and sales strategy that supports lead generation, growth and value creation for GD3’s drug discovery services. He also contributes to defining the technical strategy, overseeing the creation and dissemination of technical marketing material, and provides direct client facing support for GD3‘s portfolio companies, Invivotek and PharmOptima. In terms of corporate development Prabal is involved in M&A’s, execution of in-licensing and out-licensing transactions, and developing term sheets for partnership/collaborations.

Extra Info

Prabal brings 9 years of experience in the Drug Discovery services to GD3. He was previously Director of Business Development at HuMurine Technologies where he led the creation and implementation of strategies for commercialization of translational animal models.

Prabal received his MS in Life Sciences from University of Indore in India. He earned his Ph.D. in Microbiology/Immunology at SUNY Upstate Medical University in Syracuse, NY.